
Apollomics Inc (APLM) Stock Forecast & Price Target
Apollomics Inc (APLM) Analyst Ratings
Bulls say
Apollomics Inc., a clinical-stage biopharmaceutical company, showcases promising advancements in oncology therapies, particularly with vebreltinib (APL-101) and uproleselan (APL-106). Vebreltinib has demonstrated an impressive 66.7% objective response rate (ORR) in its Phase 1/2 trials, outperforming comparable MET inhibitors, which have shown ORRs of 40-55%, thereby indicating its potential to address significant unmet medical needs in MET-amplified cancers. Furthermore, uproleselan's ability to enhance chemotherapy efficacy in acute myeloid leukemia through the blockade of E-selectin presents additional avenues for successful treatment options, contributing positively to Apollomics's overall growth prospects.
Bears say
Apollomics Inc. is projected to experience significant net losses, with expectations of $2.11 per share for 2023 and $0.66 per share for 2024, raising concerns regarding its financial health. The company faces numerous risks, including potential negative clinical data, slower development timelines, setbacks in clinical studies, and the possibility of regulatory approval failures, which could hinder its growth and profitability. Additionally, the company's reliance on equity financing and the risk of dilution, coupled with a complex corporate structure, contribute to a challenging outlook for investors.
This aggregate rating is based on analysts' research of Apollomics Inc and is not a guaranteed prediction by Public.com or investment advice.
Apollomics Inc (APLM) Analyst Forecast & Price Prediction
Start investing in Apollomics Inc (APLM)
Order type
Buy in
Order amount
Est. shares
0 shares